Short Interest in XORTX Therapeutics Inc. (NASDAQ:XRTX) Drops By 58.5%
by Tristan Rich · The Markets DailyXORTX Therapeutics Inc. (NASDAQ:XRTX – Get Free Report) saw a large decline in short interest during the month of May. As of May 29th, there was short interest totaling 22,256 shares, a decline of 58.5% from the May 14th total of 53,649 shares. Approximately 1.4% of the company’s shares are sold short. Based on an average daily volume of 36,983 shares, the days-to-cover ratio is currently 0.6 days.
XORTX Therapeutics Price Performance
Shares of XRTX stock remained flat at $2.18 during trading hours on Friday. 17,433 shares of the stock traded hands, compared to its average volume of 29,608. The business’s fifty day moving average is $2.40 and its two-hundred day moving average is $2.50. XORTX Therapeutics has a 52-week low of $1.73 and a 52-week high of $7.05. The firm has a market capitalization of $3.77 million, a PE ratio of -0.83 and a beta of 0.74.
XORTX Therapeutics (NASDAQ:XRTX – Get Free Report) last issued its quarterly earnings data on Friday, May 15th. The technology company reported ($0.58) EPS for the quarter.
Analyst Upgrades and Downgrades
Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of XORTX Therapeutics in a report on Friday, March 27th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, XORTX Therapeutics has a consensus rating of “Sell”.
Check Out Our Latest Analysis on XRTX
Hedge Funds Weigh In On XORTX Therapeutics
An institutional investor recently raised its position in XORTX Therapeutics stock. Citadel Advisors LLC lifted its stake in XORTX Therapeutics Inc. (NASDAQ:XRTX – Free Report) by 124.4% during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 86,326 shares of the technology company’s stock after acquiring an additional 47,858 shares during the quarter. Citadel Advisors LLC owned 1.24% of XORTX Therapeutics worth $70,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 0.23% of the company’s stock.
XORTX Therapeutics Company Profile
Xyratex Ltd (Xyratex) is a provider of data storage technology, including modular solutions for the enterprise data storage industry and hard disk drive (HDD) capital equipment for the HDD industry. Xyratex operates in two segments: Networked Storage Solutions (NSS) and Storage Infrastructure (SI). Its NSS products are primarily HDD based data storage subsystems and solutions, which it provides to original equipment manufacturers. Its SI products consist of HDD manufacturing process equipment, which it sells directly to manufacturers of HDDs and their component suppliers.